CEP37440

CAS No. 1391712-60-9

CEP37440( CEP37440 | CEP 37440 | CEP-37440 )

Catalog No. M17273 CAS No. 1391712-60-9

CEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 40 In Stock
5MG 65 In Stock
10MG 115 In Stock
25MG 242 In Stock
50MG 462 In Stock
100MG 671 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CEP37440
  • Note
    Research use only, not for human use.
  • Brief Description
    CEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK).
  • Description
    CEP-37440 is an orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon administration, ALK-FAK inhibitor CEP-37440 selectively binds to and inhibits ALK kinase and FAK kinase. The inhibition leads to disruption of ALK- and FAK-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK- and FAK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors.
  • In Vitro
    Cell Viability Assay Cell Line:FC-IBC02, KPL4, SUM190, MDA-IBC03 and SUM149 cells Concentration:0, 300, 1000, 2000 and 3000 nM Incubation Time:0, 24, 48, 72, 96, 120, 144, 168, and 192 hours Result:Reduced the proliferation of three out of five IBC cell lines at low concentration. Inhibited the proliferation almost completely at 3000 nM concentration.Western Blot Analysis Cell Line:FC-IBC02, SUM 190, and KPL4 cells Concentration:1000 nM Incubation Time:0, 48, 72, 96 and 120 hours Result:Decreased phospho-FAK1 by half in FC-IBC02, SUM190, and KPL4 cells after 48 hours.
  • In Vivo
    ——
  • Synonyms
    CEP37440 | CEP 37440 | CEP-37440
  • Pathway
    Microbiology/Virology
  • Target
    HCV
  • Recptor
    ALK| FAK
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1391712-60-9
  • Formula Weight
    580.12
  • Molecular Formula
    C30H38ClN7O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 41 mg/mL. 70.68 mM
  • SMILES
    CNC(=O)c1ccccc1Nc1nc(ncc1Cl)Nc1c(c2c(C[C@H](CCC2)N2CCN(CC2)CCO)cc1)OC
  • Chemical Name
    (S)-2-((5-chloro-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Iragavarapu C, et al. J Hematol Oncol. 2015 Feb 27;8(1):17.
molnova catalog
related products
  • Velpatasvir

    Velpatasvir (GS-5816) is a second generation, pan-genotypic inhibitor of HCV NS5A, demonstrates a high barrier to resistance in HCV replicon assays.

  • Uprifosbuvir

    A novel uridine nucleotide analog HCV NS5B polymerase inhibitor for treatment of HCV infection combined with Grazoprevir and Ruzasvir.

  • Sofosbuvir impurity ...

    Sofosbuvir impurity F is both a diastereomer of Sofosbuvir and an impurity of Sofosbuvir which is an inhibitor of HCV RNA replication.